Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report.

Durvalumab 联合化疗可能将不可切除的 IV 期阴茎鳞状细胞癌转化为可切除疾病 ： 一例病例报告。

• 影响指数: 3.109
• 发表时间: 12 2022 26
• 来源期刊: Curr Oncol
• DOI: 10.3390/curroncol30010026
• PMID: 36661675
• 文章类型: Case Reports
• 中科院分区: Q4
• 方向: 医学
• 作者列表: Chen HX,Lin CC,Lin CH,Yang CR

关键词: combination; durvalumab; immunotherapy; penile cancer; squamous cell carcinoma

Mesh: Male; Humans; Penile Neoplasms / drug therapy pathology; Carcinoma, Squamous Cell / pathology; Combined Modality Therapy; Lymph Nodes / pathology

Abstract

Penile squamous cell carcinoma is a rare disease entity with poor overall survival in an advanced stage. Few studies have investigated the role of immunotherapy in advanced penile squamous cell carcinoma. Herein, we report a case of stage IV unresectable penile squamous cell carcinoma presenting with anal bleeding and urethra obstruction who responded dramatically to combination therapy of durvalumab and cisplatin-based chemotherapy. The patient had HPV-positive penile squamous cell carcinoma, cT3N3M0, with concomitant anus squamous cell carcinoma. After 2 months of the combination treatment, almost all bulky inguinal lymph nodes shrank, and the main tumor of the anus and penis responded completely. A durable response was seen 16 months after initiating the combination therapy. This case report highlights the potential role of the combination of immunotherapy and chemotherapy in patients with advanced penile cancer. The promising results of this combination resulted in the conversion of unresectable disease to a potentially curable disease.

摘要

阴茎鳞状细胞癌是一种罕见的疾病实体，晚期总体生存率低。很少有研究探讨免疫治疗在晚期阴茎鳞状细胞癌中的作用。在这里，我们报告了1例IV期不可切除的阴茎鳞状细胞癌,表现为肛门出血和尿道梗阻,对durvalumab和以顺铂为基础的化疗联合治疗有显著反应.该患者患有HPV阳性阴茎鳞状细胞癌，cT3N3M0，伴有肛门鳞状细胞癌。联合治疗2个月后，几乎所有巨大的腹股沟淋巴结都缩小了,肛门和阴茎的主要肿瘤完全反应。在开始联合治疗16个月后观察到持久的反应。该病例报告强调了免疫治疗和化疗联合治疗在晚期阴茎癌患者中的潜在作用。这种组合的有希望的结果导致不可切除的疾病转化为潜在可治愈的疾病。